EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Long‐term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry

Sławomir Teper iD, Daniel Ledwoń iD, Adam Sendecki iD, Patrycja Romaniszyn-Kania iD, Aleksandra Tuszy iD, Julia Nycz iD, Andrzej W Mitas iD, Małgorzata Figurska iD, Edward Wylęgała iD, Marek Rękas iD

Acta Ophthalmologica · 2026

DOI: 10.1111/aos.70040 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Ophthalmologica, 2026. Verfasst von Sławomir Teper und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chair and Clinical Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. Hauptthemen laut MEDLINE: Registries, Visual Acuity, Ranibizumab, Wet Macular Degeneration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate long‐term outcomes of anti‐VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry.

Methods

The cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow‐up through 31 October 2023. Long‐term follow‐up (>5 years) was conducted for 7631 eyes. Statistical comparisons and multivariate logistic regression analysed differences between treatment failure and long‐term treatment, treatment effectiveness, drug efficacy and predictive factors.

Results

The relative risk of nAMD in females was 1.45. By the last follow‐up, 17 518 (48.6%) patients discontinued treatment due to patient‐related factors, 7202 (20.0%) due to treatment failure, 6285 (17.4%) for other reasons and 5065 (14.0%) due to death or clinical complications. Long‐term patients were significantly younger, more of them were previously treated, received fewer injections per year and had better baseline BCVA and lower CRT than the failure group. Females and previously treated patients had a higher likelihood of long‐term therapy, while older age and initial ranibizumab treatment increased the risk of failure. Patients with an initial BCVA >0.4 logMAR had significantly worse BCVA outcomes, while CRT and treatment strategy showed no significant differences. Introduction of programme exclusion if treatment gap >4 months reduced long breaks, increased injection numbers, slightly lowered BCVA and had no significant effect on CRT.

Conclusion

Early visual acuity response, drug choice (aflibercept), and healthcare system modifications influence long‐term success and adherence in nAMD management. While systemic changes improved continuity and injection frequency, they did not enhance visual outcomes, highlighting the need for individualized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesVisual AcuityRanibizumabWet Macular DegenerationHumansFemaleMalePolandAngiogenesis InhibitorsIntravitreal InjectionsFollow-Up StudiesAgedTreatment OutcomeTime FactorsMiddle AgedVascular Endothelial Growth Factor AAged, 80 and overRetrospective StudiesReceptors, Vascular Endothelial Growth FactorTomography, Optical CoherenceRecombinant Fusion Proteins

Stichwörter der Autor:innen

anti‐VEGF therapylong‐term outcomesnational registryneovascular AMDreal‐world evidence

Substanzen

Angiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AafliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Chair and Clinical Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
  • Scientific Research Facility, Branch in Bielsko-Biala, Medical University of Silesia, Katowice, Poland.
  • Faculty of Biomedical Engineering, Silesian University of Technology, Zabrze, Poland.
  • Institute of Biomedical Engineering and Informatics, Technische Universität Ilmenau, Ilmenau, Germany.
  • Department of Ophthalmology, Military Institute of Medicine, Central Clinical Hospital of the Ministry of National Defense, Warsaw, Poland.
  • National Consultant in Ophthalmology, Ministry of Health, Warsaw, Poland.

ORCID-Profile: Sławomir Teper, Daniel Ledwoń, Adam Sendecki, Patrycja Romaniszyn-Kania, Aleksandra Tuszy, Julia Nycz, Andrzej W Mitas, Małgorzata Figurska, Edward Wylęgała, Marek Rękas

Zitieren

APA

Teper, S., Ledwoń, D., Sendecki, A., Romaniszyn-Kania, P., Tuszy, A., Nycz, J., Mitas, A. W., Figurska, M., Wylęgała, E., & Rękas, M. (2026). Long‐term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry. Acta Ophthalmologica. https://doi.org/10.1111/aos.70040

Vancouver

Teper S, Ledwoń D, Sendecki A, Romaniszyn-Kania P, Tuszy A, Nycz J, et al. Long‐term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry. Acta Ophthalmologica. 2026. doi:10.1111/aos.70040

BibTeX
@article{Teper2026,
  author = {Teper, Sławomir and Ledwoń, Daniel and Sendecki, Adam and Romaniszyn-Kania, Patrycja and Tuszy, Aleksandra and Nycz, Julia and Mitas, Andrzej W and Figurska, Małgorzata and Wylęgała, Edward and Rękas, Marek},
  title = {Long‐term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry},
  journal = {Acta Ophthalmologica},
  year = {2026},
  doi = {10.1111/aos.70040}
}
Kostenlos starten →